CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Peak Bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Peak Bio Inc
4900 Hopyard Road, Suite 100
Phone: (925) 463-4800p:925 463-4800 PLEASANTON, CA  94588  United States Fax: (845) 818-3588f:845 818-3588
This company ceased filing statements with the SEC on 11/15/2024.
This company is no longer actively traded on any major stock exchange.
Business Summary
Peak Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The Company's pipeline includes an antibody-drug-conjugate (ADC) platform that includes novel toxins and linkers coupled with important cancer antibody targets and a Phase 2-ready neutrophil elastase inhibitor for alpha1 anti-trypsin deficiency disorder (AATD). Its clinical stage, phase 2 ready asset, PHP-303 (its lead product candidate), is being investigated for the treatment of AATD, a rare genetic disorder and exploring opportunities with PHP-303 for the treatment of acute respiratory distress syndrome (ARDS). PHP- 303 is an oral, once daily, potent, selective small molecule inhibitor of neutrophil elastase (NE) designed to inhibit the bioactive form of NE. Its proprietary toxin, PH-1 or Thailanstatin (a spliceosome modulator) is being used to generate its first pipeline of novel ADC product candidates.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer HoyoungHuh 54 8/31/2024 1/1/2015
Acting Chief Financial Officer Timothy M.Cunningham 62 11/1/2022 11/1/2022
Executive Director, Head of Oncology SatyajitMitra 49 11/1/2022 11/1/2022
Director SandipPatel 8/8/2024 8/8/2024
Independent Director JamesNeal 68 11/1/2022 11/1/2022

Business Names
Business Name
Ignyte Korea Co, Ltd.
Peak Bio Co., Ltd.

General Information
Outstanding Shares: 23,124,888 (As of 8/5/2024)
Shareholders: 50
Stock Exchange: OTC
Federal Tax Id: 852448157
Fax Number: (845) 818-3588


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024